Overview

Conjugate Vaccine Market is poised to value over CAGR of over 12.5% during the forecast period 2022 to 2028.

Conjugate denotes a connection or joining. Conjugate vaccines combine a weaker component, often a carrier protein or antigen, with a specific component of the germ to produce an extremely potent immune response that is specifically directed at essential components of the virus or bacteria. The protection of newborns and toddlers, longer-lasting immunity, their impact on bacterial carriage, and the development of herd immunity are some benefits of conjugate vaccines. The pneumococcus, also known as Streptococcus pneumoniae, is the bacterium that causes pneumococcal illness. It can result in infections of the blood, brain, and lungs. Children with pneumococcal illness typically have health issues before the age of 5. These include ear infections, blood infections, and meningitis. Both adults and children can get the sickness prevented by the vaccine. The pneumococcal conjugate vaccine is one of the two Pneumococcal illness vaccines that are now available. The market is expanding primarily due to technological improvements, rising regulatory approvals for conjugate vaccines, rising prevalence of diseases brought on by bacteria including Streptococcus pneumoniae and Neisseria meningitidis, and increased usage of conjugate vaccinations for adults. Contrarily, limited vaccination accessibility in distant locations and the difficult conjugate vaccine production process limit market expansion. As a result, numerous top vaccine producers are engaged in research and development for the creation of vaccinations. The need for PCV vaccines is increasing since pneumonia is a serious problem in many nations. It is anticipated that rising rates of infectious diseases including typhoid, pneumonia, and other ones will fuel the rise of conjugate vaccines globally.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Conjugate Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Conjugate Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Conjugate Vaccine Market:
• Bharat Biotech
• Biological E
• GlaxoSmithKline, plc
• Merck and Company
• Novartis AG
• Pfizer, Inc
• Sanofi Pasteur
• Serum Institute of India.
• Astellas Pharma Inc.
 Mitsubishi Tanabe Pharma Corporation
(Note: The list of the major players will be updated with the latest market scenario and trends)

Conjugate Vaccine Market Segmentation:
By Type
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease Indication
• Pneumococcal
• Influenza
• Diptheria tetanus Pertussis
• Meningococcal
• Others

By Pathogen Type
• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral and Bacterial) Conjugate Vaccine

By Patient Stage
• Pediatrics Conjugate Vaccine
• Adults Conjugate Vaccine

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Conjugate Vaccine Market By Type, By Disease Indication, By Pathogen Type, By Patient Stage and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Disease Indicationology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Conjugate Vaccine Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Conjugate Vaccine Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Conjugate Vaccine Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Conjugate Vaccine Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Monovalent Conjugate Vaccines
  7.2. Multivalent Conjugate Vaccines
 
8. Global Conjugate Vaccine Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Pneumococcal
  8.2. Influenza
  8.3. Diagnosis
  8.4. Meningococcal
  8.5. Others
       
9. Global Conjugate Vaccine Market, By Pathogen Type Historical Analysis and Forecast 2022-2028 (USD Million)  
  9.1. Bacterial Conjugate Vaccine
  9.2. Viral Conjugate Vaccine
  9.3. Combination (Viral and Bacterial) Conjugate Vaccine
 
10. Global Conjugate Vaccine Market, By Patient Stage Historical Analysis and Forecast 2022-2028 (USD Million)  
   10.1. Pediatrics Conjugate Vaccine
   10.2. Adults Conjugate Vaccine
   
11. North America Conjugate Vaccine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  11.1. Introduction
  11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       11.2.1. U.S.A
       11.2.2. Canada
       11.2.3. Mexico
  11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Conjugate Vaccine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Brazil
         12.2.2. Venezuela
         12.2.3. Argentina
         12.2.4. Rest of Latin America
   12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Conjugate Vaccine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Germany
         13.2.2. U.K        
         13.2.3. France
         13.2.4. Italy
         13.2.5. Spain
         13.2.6. Russia
         13.2.7. Poland
         13.2.8. Rest of Europe
   13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Conjugate Vaccine Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. Japan
         14.2.2. China
         14.2.3. India
         14.2.4. Australia and New Zealand
         14.2.5. ASEAN
         14.2.6. Rest of Asia Pacific
   14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         15.2.1. GCC
         15.2.2. Israel
         15.2.3. South Africa
         15.2.4. Rest of MEA
   15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape  
   16.1. Global Landscape - Key Players, Revenue and Presence
   16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   16.3. Global Emerging Companies
   16.4.  North America - Market Share Analysis and Key Regional Players
   16.5.  Europe - Market Share Analysis and Key Regional Players
   16.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   16.7.  Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)
   17.1. Bharat Biotech
         17.1.1. Company Overview
         17.1.2. Type Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2. Biological E
         17.2.1. Company Overview
         17.2.2. Type Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. GlaxoSmithKline, plc
         17.3.1. Company Overview
         17.3.2. Type Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. Merck and Company
         17.4.1. Company Overview
         17.4.2. Type Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
   17.5. Novartis AG
         17.5.1. Company Overview
         17.5.2. Type Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
   17.6. Pfizer, Inc
         17.6.1. Company Overview
         17.6.2. Type Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. Sanofi Pasteur
         17.7.1. Company Overview
         17.7.2. Type Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Serum Institute of India.
         17.8.1. Company Overview
         17.8.2. Type Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. Astellas Pharma Inc.
         17.9.1. Company Overview
         17.9.2. Type Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
   17.10.Mitsubishi Tanabe Pharma Corporation
         17.10.1. Company Overview
         17.10.2. Type Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview

18. Pre and Post COVID-19 Impact
   18.1. Positive influence on the healthcare industry
   18.2. The financial disruption of the manufacturing sector
   18.3. Impact of COVID-19 on emerging companies
   18.4. Significant mandates in the healthcare regulations initiated by administrations
   18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures